Lyme Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Lyme disease is a multi-organ animal-borne disease caused by bacteria – spirochetes of the Borrelia species classified as Borrelia burgdorferi (Bb) strain (sensu lato). It can manifest as early localized, early disseminated disease, or late disease. The innate and adaptive immune systems contribute to the inflammatory response resulting in clinical symptoms. Regardless of the clinical presentation, the vast majority of patients who are treated for Lyme disease with short courses of appropriate antibiotics do extremely well. The clinical presentation varies depending on the stage of the illness and includes erythema migrans, carditis, central nervous system disease, and arthritis. Regardless of the clinical presentation, most patients with Lyme disease have a resolution of their clinical symptoms when treated with appropriate antimicrobials.
·
The incidence of Lyme disease in the United
States ranges between 8 to 11.5 cases per 100,000 people in 2020.
Thelansis’s “Lyme Disease Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Lyme
Disease treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Lyme Disease across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Lyme Disease Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment